Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (NASDAQ:BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.
不自然產品公司（UNP），一家開發口服給藥的宏環肽以應對之前無法藥物化的靶點的生物技術公司，今天宣佈BridgeBio Pharma公司（納斯達克：BBIO）已行使其選項，以獲得使用UNP的人工智能支持的大規模平行化學平台發現的宏環肽候選物的許可。
This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential of macrocyclic peptides as a novel therapeutic modality for rare diseases and oncology. Macrocyclic peptides are a unique class of therapeutic compounds characterized by large, cyclic structures that offer significant advantages over traditional therapies such as small molecules and monoclonal antibodies. Their unique structure provides high stability, potent binding affinity, and the ability to access difficult-to-reach intracellular targets, positioning them as a promising therapeutic class.
這一里程碑標誌着兩家公司合作的重要進展，並強化了宏環肽作爲罕見疾病和腫瘤學新型治療方式的潛力。宏環肽是一類獨特的治療化合物，以大型環狀結構爲特徵，相較於傳統療法如小分子和單克隆抗體具有顯著優勢。它們獨特的結構提供了高穩定性、強效的結合力，以及接觸難以到達的細胞內靶點的能力，使其成爲一種有前途的治療類別。